Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors
- 158 Downloads
Purpose: This is a first-in-human, phase I, dose-escalation study to determine the maximum tolerated dose (MTD) of intravenous, flat-dosed ST-1968 (namitecan), a new hydrophilic camptothecan derivative. Methods: Namitecan was administered intravenously over 2 h on day 1 and day 8 every 21 days (D1-D8-Q21D), starting at a flat dose of 2.5 mg, and increased according to a 3 + 3 cohort design. Due to frequent skipping of day 8 dosing for cytopenias, the study was expanded to test namitecan dosing on day 1 every 21 days (D1-Q21) at a starting dose of 17.5 mg. Major dose-limiting toxicity (DLT) was defined as grade (G) 4 neutropenia persisting >5 days, febrile neutropenia, G3 thrombocytopenia or G2 non-hematological toxicity. Results: Thirty-four patients were included into the D1-D8-Q21D group (2.5, 5, 10, 15, 17.5, 20 mg dosing cohorts), 29 patients into the D1-21D group (17.5, 20, 23, 27, 30 mg dosing cohorts). Neutropenia was the DLT in both groups, with 15 mg being defined as the recommended dose (RD) for the D1-D8-Q21D group, and 23 mg for the D1-Q21D group. Non-hematological toxicity was negligible. One patient with endometrial cancer in the D1-D8-Q21D group and one patient with cholangiocellular carcinoma in the D1-Q21D group experienced a partial remission. Namitecan exhibited fully dose-proportional pharmacokinetics. Conclusions: This study demonstrates clinical safety, favourable pharmacokinetics and preliminary antitumor activity of the novel hydrophilic camptothecin analogue namitecan in patients with heavily pretreated solid malignancies, when given either on a 2 out of 3 weeks or 3-weekly regimen.
KeywordsAntineoplastic agens Namitecan Camptothecan Maximum tolerated dose Neutropenia Phase 1 clinical trial
This work was supported by Sigma-Tau V.le Shakespeare, Rome, Italy. The study has been coordinated by the Southern Europe New Drug Organization (SENDO), Via La Masa, Milano (Italy).
Compliance with ethical standards
The protocol was approved by the responsible Ethical Review Boards and Regulatory Authorities and conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent.
Conflict of interest
P. Barbieri and S. Pace are employed by Sigma-Tau (Rome, Italy). No potential conflicts of interest were disclosed by the other authors.
- 3.FDA approves irinotecan as first-line therapy for colorectal cancer (2000). Oncology (Williston Park) 14 (5):652–654Google Scholar
- 4.Pecorelli S, Ray-Coquard I, Tredan O, Colombo N, Parma G, Tisi G, Katsaros D, Lhomme C, Lissoni AA, Vermorken JB, du Bois A, Poveda A, Frigerio L, Barbieri P, Carminati P, Brienza S, Guastalla JP (2010) Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol 21(4):759–765. doi: 10.1093/annonc/mdp514 CrossRefPubMedCentralPubMedGoogle Scholar
- 5.De Cesare M, Pratesi G, Perego P, Carenini N, Tinelli S, Merlini L, Penco S, Pisano C, Bucci F, Vesci L, Pace S, Capocasa F, Carminati P, Zunino F (2001) Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 61(19):7189–7195PubMedGoogle Scholar
- 6.De Cesare M, Beretta GL, Tinelli S, Benedetti V, Pratesi G, Penco S, Dallavalle S, Merlini L, Pisano C, Carminati P, Zunino F (2007) Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series. Biochem Pharmacol 73(5):656–664. doi: 10.1016/j.bcp.2006.11.004 CrossRefPubMedGoogle Scholar
- 8.Pisano C, Zuco V, De Cesare M, Benedetti V, Vesci L, Fodera R, Bucci F, Aulicino C, Penco S, Carminati P, Zunino F (2008) Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968. Eur J Cancer 44(9):1332–1340. doi: 10.1016/j.ejca.2008.04.004 CrossRefPubMedGoogle Scholar
- 10.Pisano C, De Cesare M, Beretta GL, Zuco V, Pratesi G, Penco S, Vesci L, Fodera R, Ferrara FF, Guglielmi MB, Carminati P, Dallavalle S, Morini G, Merlini L, Orlandi A, Zunino F (2008) Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. Mol Cancer Ther 7(7):2051–2059. doi: 10.1158/1535-7163.MCT-08-0266 CrossRefPubMedGoogle Scholar
- 11.Meco D, Di Francesco AM, Cusano G, Bucci F, Pierri F, Patriarca V, Torella AR, Pisano C, Riccardi R (2012) Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models. Cancer Chemother Pharmacol 70(6):811–822. doi: 10.1007/s00280-012-1973-0 CrossRefPubMedGoogle Scholar
- 12.Cassinelli G, Zuco V, Petrangolini G, De Cesare M, Tortoreto M, Lanzi C, Cominetti D, Zaffaroni N, Orlandi A, Passeri D, Meco D, Di Francesco AM, Riccardi R, Bucci F, Pisano C, Zunino F (2012) The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochem Pharmacol 84(2):163–171. doi: 10.1016/j.bcp.2012.04.005 CrossRefPubMedGoogle Scholar
- 14.Administration USFaD (2005) Guidance for Industry - Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. http://www.fdagov/downloads/Drugs/Guidance/UCM078932pdf
- 16.Shinoda T, Kawahara H, Yoshinaga K, Shioya H, Kobayashi S, Yanaga K, Komine K (2006) Refractory Irinotecan-induced interstitial pneumonitis after treatment of metastatic lung cancer from the rectum: a case report. Jikeikai Med J 53:159–162Google Scholar
- 17.van der Bol JM, Mathijssen RH, Creemers GJ, Planting AS, Loos WJ, Wiemer EA, Friberg LE, Verweij J, Sparreboom A, de Jong FA (2010) A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res 16(2):736–742. doi: 10.1158/1078-0432.CCR-09-1526 CrossRefPubMedGoogle Scholar